BMCS Antibody–Drug Conjugates
Event
BMCS Antibody – Drug Conjugates
Date
Thursday 19th November 2026
Place
GSK, Stevenage, UK
Important links and downloads
Social Media – #BMCSADCs
Click here to submit your abstract
Click here to register for the meeting
Please click here to download the first announcement
Synopsis
Following the success of the BMCS Hot Topics Antibody-drug conjugates meeting, the BMCS are organising an in-person Antibody-Drug Conjugates meeting.
Antibody-Drug Conjugates (ADCs), alongside other targeted modalities, effectively enrich target tissues with potent payloads unsuitable for systemic administration. With several recent clinical successes, the number of new ADCs approaching the clinic is rapidly increasing. This meeting aims to highlight the technological advancements and innovations driving these ADCs, while addressing the challenges and opportunities within the field. The meeting will feature speakers from industry and academia who are at the forefront of ADC design.
Registration
Registration fees are below. Please note that these fees are excluding VAT, and VAT will be added on at checkout at the end of completing the registration form.
RSC Member: £165
Non-Member: £200
RSC Student Member: £85
Student Non-Member: £100
Please click here to register.
Want to become a member?
To join the RSC in order to qualify for discounted registration fees at all RSC, please follow this RSC link.
Abstracts
Abstract submission is still open for late poster abstracts. Please click here to submit your abstract.
Programme
| 09:00 | Registration & Tea/Coffee |
| 09:30 | Welcome and Introduction, Jo McGregor, GSK |
| 09:35 | Andrea Hernandez, Zymeworks Deconjugation to Cytotoxic Activity in Cancer and Normal Cells: Stability and Functional Characterization of Thiol-Maleimide Antibody-Drug Conjugates |
| 10:05 | David Battersby, GSK |
| 10:35 | Tea/Coffee, Posters & Exhibition |
| 11:05 | Tara Arvedson, Hexagon Bio Identification of Novel Payloads and Payload Combinations for Next-Generation ADCs |
| 11:35 | Sona Krajcovicova, University of Cambridge On-resin assembly of cysteine-reactive linkers enables controlled site-selective antibody bioconjugation and modular protein-antibody conjugate synthesis |
| 12:00 | Peter A. Szijj, Stanford University Dual cancer-selective lysosomally-targeted antibody–drug conjugates expand the ADC-druggable proteome |
| 12:25 | Flash Talk Presentations |
| 12:35 | Lunch, Posters & Exhibition |
| 13:50 | Douglas Ferguson, AstraZeneca Practical approaches for payload DMPK optimization in a drug discovery setting |
| 14:20 | Christian Hackenberger, FMP Berlin and the Humboldt University Berlin P5-labeling for Generating Highly Efficacious Antibody-Conjugates for Cancer Therapy |
| 14:50 | Tea/Coffee, Posters & Exhibition |
| 15:20 | Poster Prize |
| 15:25 | George Procopiou, Valink Therapeutics Next-generation bispecific ADCs: discovery, challenges, and outlook |
| 15:55 | Bradley Pentelute, MIT |
| 16:25 | Concluding remarks |
| 16:30 | Meeting close |
Sponsorship/Exhibition Opportunities
Please note the exhibition stand packages are now fully booked, if you are interested in exhibiting, please contact aimee.jackson@hg3.co.uk.
Exhibition stand package includes (£750 excluding VAT):
– A table and chairs
– Access to electricity
– Logo inclusion on the website, in the delegate handbook and rolling slides
– Promotional A4 page in the delegate handbook
– One stand personnel
Please click here to book your exhibition stand package.
Exhibitors
Sponsors
Supported by
Organising Committee
Sharan Bagal, AstraZeneca
Maximillian Lee, AstraZeneca
Karina Chan, GSK
Vijay Chudasama, University College London
Christine Sutton, IQVIA Laboratories
Sree Kesavan, AstraZeneca
Mahri Park, GSK
Secretariat Contact
Hg3 Conferences Ltd
+44 (0)1423 529333
E-mail
